The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Despite the success of antiretroviral therapy (ART) in controlling HIV replication, a definitive cure remains elusive due to ...
According to WHO, AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines.
The U.S. Department of Housing and Urban Development announced it would cap funding for states to help permanently house ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Leaders from homelessness response networks across the Bay Area are still reeling from the announcement of sweeping changes ...
Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...
Antimicrobial resistance directly caused 1.27 million deaths globally in 2019 and contributed to an additional 4.95 million ...
Antimicrobial resistance directly caused 1.27 million deaths globally in 2019 and contributed to an additional 4.95 million ...
The disclosure by director of Women’s Health at the Ministry of Health Dr Adesh Sirjusingh that syphilis infections among pregnant women are on the rise in Trinidad and Tobago is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback